Sodium channel blockers

Results: 51



#Item
1Beilage 1: Arzneimittelmonographien

Beilage 1: Arzneimittelmonographien

Add to Reading List

Source URL: www.sscc.ch

Language: English - Date: 2007-04-18 04:07:36
2Package leaflet: Information for the user Elaprase 2 mg/ml concentrate for solution for infusion Idursulfase ▼This medicine is subject to additional monitoring. This will allow quick identification of new safety inform

Package leaflet: Information for the user Elaprase 2 mg/ml concentrate for solution for infusion Idursulfase ▼This medicine is subject to additional monitoring. This will allow quick identification of new safety inform

Add to Reading List

Source URL: www.medicines.org.uk

Language: English
3HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORENITRAM® safely and effectively. See Full Prescribing Information for ORENITRAM.  --------------------- DOSAGE FO

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ORENITRAM® safely and effectively. See Full Prescribing Information for ORENITRAM. --------------------- DOSAGE FO

Add to Reading List

Source URL: www.orenitram.com

Language: English - Date: 2016-07-27 09:02:55
4Strensiq, INN-asfotase alfa

Strensiq, INN-asfotase alfa

Add to Reading List

Source URL: www.ema.europa.eu

Language: English - Date: 2016-01-29 11:52:49
5Microsoft Word - CINRYZE.Product Monographdoc

Microsoft Word - CINRYZE.Product Monographdoc

Add to Reading List

Source URL: www.shirecanada.com

Language: English - Date: 2016-07-27 08:19:27
6Beilage 1: Arzneimittelmonographien

Beilage 1: Arzneimittelmonographien

Add to Reading List

Source URL: www.sscc.ch

Language: English - Date: 2007-04-18 04:07:37
7LUMIZYME (alglucosidase alfa) for Injection

LUMIZYME (alglucosidase alfa) for Injection

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2010-05-26 09:39:24
8U.S. FDA approves UCB’s new epilepsy treatment, BRIVIACT®, for patients with partial-onset seizures • BRIVIACT® (brivaracetam), a new molecular entity, is indicated as adjunctive therapy in the treatment of partial

U.S. FDA approves UCB’s new epilepsy treatment, BRIVIACT®, for patients with partial-onset seizures • BRIVIACT® (brivaracetam), a new molecular entity, is indicated as adjunctive therapy in the treatment of partial

Add to Reading List

Source URL: www.ucb-usa.com

Language: English - Date: 2016-02-29 16:05:30
9STATE OF CALIFORNIA  STATEWIDE PHARMACEUTICAL PROGRAM  COMMON DRUG FORMULARY

STATE OF CALIFORNIA STATEWIDE PHARMACEUTICAL PROGRAM COMMON DRUG FORMULARY

Add to Reading List

Source URL: www.documents.dgs.ca.gov

Language: English - Date: 2016-02-29 20:46:17
10Microsoft PowerPoint - CNA certification lecture format for OTN Jan 2013.pptx [Read-Only]

Microsoft PowerPoint - CNA certification lecture format for OTN Jan 2013.pptx [Read-Only]

Add to Reading List

Source URL: swostroke.ca

Language: English - Date: 2015-07-06 16:01:15